In the past week, QNTM stock has gone up by 38.18%, with a monthly gain of 125.65% and a quarterly surge of 321.29%. The volatility ratio for the week is 11.47%, and the volatility levels for the last 30 days are 8.31% for Quantum BioPharma Ltd The simple moving average for the past 20 days is 42.33% for QNTM’s stock, with a 205.60% simple moving average for the past 200 days.
Is It Worth Investing in Quantum BioPharma Ltd (NASDAQ: QNTM) Right Now?
The stock has a 36-month beta value of 0.54. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for QNTM is 2.38M, and at present, short sellers hold a 2.95% of that float. On June 13, 2025, the average trading volume of QNTM was 582.76K shares.
QNTM) stock’s latest price update
The stock price of Quantum BioPharma Ltd (NASDAQ: QNTM) has jumped by 23.62 compared to previous close of 15.37. Despite this, the company has seen a gain of 38.18% in its stock price over the last five trading days. globenewswire.com reported 2025-06-03 that TORONTO, June 03, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces its response to information about certain stock trading platforms as well as misinformation being circulated on certain social media channels. Certain stock trading platforms mistakenly have the Quantum BioPharma name changed to Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) after the news release was issued on May 29, 2025. Quantum BioPharma has not changed its name.
QNTM Trading at 95.13% from the 50-Day Moving Average
After a stumble in the market that brought QNTM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.20% of loss for the given period.
Stock Fundamentals for QNTM
The total capital return value is set at -3.81. Equity return is now at value -235.05, with -137.74 for asset returns.
Based on Quantum BioPharma Ltd (QNTM), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -7.15. The debt to equity ratio resting at 0.22. The interest coverage ratio of the stock is -44.85.
Currently, EBITDA for the company is -13.69 million with net debt to EBITDA at 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.96.
Conclusion
To sum up, Quantum BioPharma Ltd (QNTM) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
